Introduction to Butinib 140 MG (Ibrutinib) Capsules:

Butinib 140 , expertly formulated by Beacon Pharmaceuticals Ltd. and supplied by Onco Solution, is a breakthrough medication used in the treatment of several types of blood cancers. Ibrutinib, the active ingredient, is a Bruton’s tyrosine kinase (BTK) inhibitor that interferes with cancer cell growth and survival.

Description: Butinib 140 MG (Ibrutinib) Capsules:

Butinib 140 contains Ibrutinib, a potent inhibitor of Bruton’s tyrosine kinase (BTK). By blocking this enzyme, Ibrutinib disrupts crucial signaling pathways that promote the growth and survival of cancerous B cells, leading to the inhibition of cancer progression.

Benefits of Butinib 140 MG (Ibrutinib) Capsules:

• Targeted Therapy: Specifically inhibits BTK, which is critical for the proliferation and survival of malignant B cells.
• Proven Efficacy: Demonstrates significant clinical benefits in various blood cancers.
• Oral Administration: Convenient once-daily oral dosing.

Clinical Use:

Butinib 140 MG is indicated for the treatment of several blood cancers, including:

• Chronic Lymphocytic Leukemia (CLL): Including patients with 17p deletion.
• Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.
• Waldenström’s Macroglobulinemia (WM): As a first-line treatment and for relapsed/refractory cases.

Dosage and Administration:

The dosage of Butinib 140 MG should be determined by a healthcare professional based on the specific type of cancer, patient’s condition, and response to treatment. Typically, it is taken orally once daily with a glass of water. The capsules should not be opened, broken, or chewed.

Manufacturer: Beacon Pharmaceuticals Ltd.:

Beacon Pharmaceuticals Ltd. is dedicated to producing high-quality pharmaceutical products. Their commitment to innovation and strict adherence to quality standards ensure that Butinib 140 MG meets the highest levels of efficacy and safety.

Supplier: Onco Solution:

Onco Solution, a trusted supplier of Butinib 140 MG, ensures the timely availability of this critical medication to healthcare providers and patients. Their dedication to excellence in distribution guarantees reliable access to Butinib for the treatment of blood cancers.

Storage Conditions:

• Store Butinib 140 MG capsules at room temperature (20°C to 25°C).
• Keep in a cool, dry place away from direct sunlight and moisture.
• Keep out of reach of children.

Conclusion:

Butinib 140 MG (Ibrutinib) Capsules provide an advanced treatment option for patients with various blood cancers. Manufactured by Beacon Pharmaceuticals Ltd. and supplied by Onco Solution, this targeted therapy offers significant clinical benefits, contributing to better disease management and improved patient outcomes. Trust Butinib for effective and reliable cancer treatment.